Onkologie. 2010:4(2):68-71

Current trends in prostate cancer diagnosis

Ondřej Kaplan, Kamil Belej, Oto Kőhler
Urologické oddělení, Ústřední vojenská nemocnice, Praha

Historically, the prostate was evaluated for cancer by simple digital rectal examination, and biopsy to obtain a tissue diagnosis of cancor

was performed blindly. Current dignosis of prostate cancer is based on digital rectal examination and testing of prostate specific antigen

level in serum. Biopsy techniques were developed to incorporate ultrasound guidance. Methods have several shortcomings even if

used in combination. Low sensitivity often leads to repeat biopsy. The only possibility how to overcome this unfavourable situation is

to discover different methods of prostate cancer detection.

Keywords: prostate cancer, diagnosis, PSA, PCA3

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kaplan O, Belej K, Kőhler O. Current trends in prostate cancer diagnosis. Onkologie. 2010;4(2):68-71.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kolombo I, Poršová M, Zemanová I a kol. Prostatický specifický antigen (PSA) a digitální rektální vyšetření (DRE) v diagnostice karcinomu prostaty. Urol pro praxi 2008; 9(2): 83-88.
    2. Jansen FH, Roobol M, Bangma CH, van Schaik RH. Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem 2008; 54(12): 1999-2006. Go to original source... Go to PubMed...
    3. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organconfined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270(8): 948-954. Go to original source...
    4. Belej K. Transrektální biopsie prostaty v diagnostice karcinomu prostaty. Urol pro praxi 2009; 1: 7-10.
    5. Wink M, Frauscher F, Cosgrove D, et al. Contrast-enhanced ultrasound and prostate cancer; A Multicentre European Research Coordination Project. Eur Urol 2008; 54(5): 982-993. Go to original source... Go to PubMed...
    6. Pallwein L, Mitterberger M, Pelzer A, et al. Ultrasound of prostate cancer: recent advances. Eur Radiol 2008; 18: 707-715. Go to original source... Go to PubMed...
    7. Braeckman J, Autier P, Soviny C, et al. The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers. BJU Int 2008; 11: 1560-1565. Go to original source... Go to PubMed...
    8. Vik V, Šácha P, Koukolík F, Konvalinka J, et al. Co nového víme o PSMA (prostatický specifický membránový antigen): z pohledu urologa. Urol listy 2007; 5(4): 10-13.
    9. Ploussard G, de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010; 7: 101-109. Go to original source... Go to PubMed...
    10. Bussemakers MJ, van Bokhoven A, Verhaegh GW, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59(23): 5975-5979. Go to PubMed...
    11. Popa I, Fradet Y, Beaudry G, et al. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 2007; 20: 1121-1127. Go to original source... Go to PubMed...
    12. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3 (PCA3)), a highly prostate cancer-specific gene. Urology 2003; 62(5 Suppl 1): 34-43. Go to original source... Go to PubMed...
    13. Klečka J, Hora M, Pešta M, Holubec L, Topolčan O, Eret V. DD3 (Differential Display Code 3) - nový marker v diagnostice karcinomu prostaty. Výroční konference České urologické společnosti ČLS JEP, Plzeň, 10.-12. 10. 2007 (abstrakt). Čes Urol 2007; 11: 20.
    14. Hessels D, Klein Gunnewiek JM, van Oort I, et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003; 44(1): 8-15. Go to original source... Go to PubMed...
    15. Haese A, de la Taille A, van Poppel H, et al. Clinical utility of PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-1088. Go to original source... Go to PubMed...
    16. Deras IL, Aubin SM, Blase A, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179(4): 1587-1592. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.